Accessing Innovative Medicines in China: A Guide for International Patients
- MedBridgeNZ
- 7 hours ago
- 8 min read
Updated: 6 hours ago
Key Takeaways
The Chinese healthcare system provides structured pathways to access innovative medicines through National Medical Products Administration (NMPA) approvals and special medical zones.
While 3,159 medicines are included in the national reimbursement catalog, institutional availability depends on specific hospital formularies and centralized procurement cycles.
For some medicines and indications, public medicine prices or overall treatment budgets in China may be financially competitive. Any comparison should account for the same medicine, dose, treatment duration, price basis, hospital charges, and cross-border costs.
Accessing these therapies requires rigorous administrative coordination, including the preparation of medical records, pathology and imaging materials, hospital routing, institutional review, and cross-border compliance planning.
Quick Answer
International patients may explore innovative medicine access in China when certain treatments are unavailable, subject to long wait times, or financially difficult to obtain in their home country. MedBridgeNZ uses a four-pathway working framework for explaining medicine access: medicines already stocked by a hospital; approved medicines not routinely stocked; medicines dispensed through designated dual-channel pharmacies; and eligible special-use products evaluated by designated institutions in Boao Lecheng. These are practical explanatory categories, not official regulatory classifications. Clinical suitability and medicine availability are always determined by the receiving hospital.
Why Do International Patients Explore Medicine Access in China?
Some patients consider treatment in China when a medicine for oncology, rare diseases, autoimmune conditions, or other complex indications is unavailable, delayed, or unaffordable in their home market.
Depending on the diagnosis and the receiving hospital’s assessment, China may offer access to the same medicine, a different medicine within the same therapeutic class, or another clinically appropriate hospital pathway. Medicines within the same class should not be assumed to be clinically equivalent. Patients investigate these cross-border institutional pathways to bridge the gap, seeking financially viable treatment avenues or specific clinical protocols that are legally administered in China's highly regulated tertiary hospitals.
How Does Innovative Medicine Access in China Work?
Innovative medicine access in China depends on several regulatory and institutional levels, including national approval, reimbursement policy, hospital formularies, procurement arrangements, and clinical evaluation.
Approval & Registration: The NMPA regulates medicine approval and registration.
National Reimbursement: The National Healthcare Security Administration (NHSA) manages national reimbursement policy, negotiated-medicine listings, and related access mechanisms. Following the 2024 catalog adjustment, which took effect in 2025, China’s national reimbursement catalog contained 3,159 medicines, including 91 newly added medicines. In 2026, the NHSA stated that 199 innovative medicines had entered reimbursement coverage through eight consecutive years of negotiations. This does not mean that international self-paying patients automatically qualify for reimbursement.
Institutional Availability: Individual hospitals determine whether a medicine is included in their formulary and available through their procurement system. Because formulary access, international-patient services, and specialty strengths differ by institution, patients may review MedBridgeNZ’s featured hospital profiles in China to understand the types of facilities available. Inclusion on this page does not guarantee hospital acceptance, clinical suitability, or medicine availability.
The Four Practical Access Pathways
Please note: For practical explanation, MedBridgeNZ uses the following four-pathway working framework. These labels are not official Chinese regulatory classifications. Clinical suitability and final access are determined by the treating institution, not by MedBridgeNZ.
Pathway | Medicine Status | Typical Access Route | Main Limitations & Considerations |
Pathway A | NMPA-approved and routinely stocked by the hospital. | Hospital prescription and hospital dispensing/administration. | Subject to appointment availability, clinical suitability, and real-time hospital stock. |
Pathway B | NMPA-approved but not routinely stocked by the target hospital. | Hospital formulary introduction or case-specific coordination. | Subject to pharmacy committee decisions and procurement timelines, which may vary significantly. |
Pathway C | NMPA-approved and available through a designated dual-channel route. | Prescribing institution plus designated external pharmacy. | Subject to local rules, prescription validity, and external pharmacy stock. |
Pathway D | Not routinely approved in mainland China but potentially eligible for special use in Boao Lecheng. | Evaluation by a designated medical institution. | Requires strict clinical necessity evaluation, institutional approval, case filing, and traceability. |
Risk Summary: Pathway B and Pathway D generally involve less predictable timelines than routine hospital access. None of the four pathways guarantees medicine availability, hospital acceptance, a lower price, or treatment suitability.
What Is the Boao Lecheng Special-Use Pathway?
For specific innovative medicines not yet broadly available, the Boao Lecheng system operates under distinct administrative protocols.
Definition: A designated medical tourism pilot zone in Hainan, China, authorized to utilize specific overseas medicines and medical devices under strict regulatory oversight.
Function: It provides a legally compliant mechanism for hospitals to use clinically urgent products that are approved abroad but have not yet achieved broad NMPA registration in mainland China.
Typical Use Case: International patients whose treating institution wishes to evaluate whether a clinically urgent product may qualify for special use under the Boao Lecheng framework.
Why This Matters: It offers a regulated institutional pathway for certain eligible special-use medicines and medical products, subject to the designated institution’s clinical assessment, product availability, regulatory filing, and traceability requirements.
Does a Lower Medicine Price Mean a Lower Total Cost?
For some imported medicines and domestic innovative drugs, navigating compliant hospital pathways in China may offer financially competitive public drug costs. However, a published medicine price is not the same as a hospital quotation or the patient’s final cost.
When evaluating the financial viability of medical travel, international patients must consider a comprehensive total-cost model:
Public Price vs. Hospital Price: Published reference prices (such as an overseas public reference price) often differ from the actual execution price at a Chinese hospital.
Total Medical Cost: The baseline budget must include specialist consultation fees, laboratory testing, pathology reviews, and infusion or pharmacy service fees.
Total Cross-Border Cost: Patients must factor in the logistical costs of travel, including appropriate visa or entry documentation, international flights, ground transportation, accommodation, and professional translation services. Our China medical tourism visa guide provides a general overview of the entry pathways international patients may need to consider.
MedBridgeNZ can help patients structure an indicative total-budget framework using available public information and hospital-provided estimates. Final charges, treatment requirements, and medicine prices are determined by the receiving institution and may change.
When Is Planned Cross-Border Coordination Not Appropriate?
MedBridgeNZ’s planned medical travel coordination service is not designed for medical emergencies, ICU transfers, or patients requiring immediate life-saving intervention. Fitness for international travel and suitability for treatment must be determined by the patient’s treating clinicians and the receiving hospital.
Cases with incomplete foundational medical documentation may require additional records before they can be submitted to a hospital or specialist for review.
Cross-Border Medicine and Return-Home Considerations
Patients intending to return home with prescribed medicine must strictly adhere to personal importation rules set by their local agencies (e.g., FDA, TGA, Health Canada, Medsafe, or HSA). These regulations typically mandate that medicines remain in original packaging, are accompanied by a valid prescription or doctor's letter, and are strictly limited to a specific supply duration (often 30 to 90 days).
Important Compliance Note: Personal import and traveller-carriage rules vary by country, residency status, medicine type, and method of transport. Quantity limits alone do not establish that importation is lawful. Patients are responsible for checking the applicable customs, medicines-regulator, and controlled-drug requirements in their destination country before travelling or transporting any medicine.
How MedBridgeNZ Can and Cannot Help
How MedBridgeNZ Can Help
Conduct an administrative completeness check and prepare records for institutional submission.
Contact potentially relevant hospitals or specialists to ask whether a remote record review, written opinion, or consultation may be arranged.
Coordinate appointments, on-the-ground travel, and bilingual support.
Explain general access pathways and total-budget components.
Help organize hospital-issued discharge and prescription documents.
MedBridgeNZ provides non-clinical support across medical-record preparation, hospital liaison, appointment coordination, travel planning, bilingual assistance, and post-treatment administration. Learn more about our medical concierge and coordination services
What MedBridgeNZ Does Not Do
Diagnose conditions or recommend a specific medicine.
Determine whether a patient is clinically eligible for a treatment.
Prescribe or dispense medicines.
Purchase, store, resell, or ship prescription medicines.
Guarantee medicine availability, hospital acceptance, or customs clearance.
Frequently Asked Questions
Can international patients submit their local medical records to Chinese tertiary hospitals for remote review prior to travel?
Potentially. Some hospitals and specialists may accept international medical records for a remote review, written opinion, or video consultation. Availability depends on the institution, specialty, documentation, and individual specialist.
What medical records may be requested for a Boao Lecheng institutional review?
Depending on the disease, requested product, and institution, records may include recent clinical notes, treatment history, imaging, pathology, laboratory results, and relevant molecular or genomic testing. These documents must be translated, summarized, or reformatted where required by the receiving hospital to enable them to conduct a formal evaluation.
How do institutional pharmacy committees in China influence the availability of innovative medicines?
Hospital pharmacy and therapeutics committees establish the institution's essential drug supply catalog. They govern the introduction and procurement of new medicines, meaning a physician can only prescribe a therapy if the committee has integrated it into the hospital's active inventory or approved a case-specific request.
Does a dual-channel pharmacy listing mean international patients receive the local reimbursed price?
No. Dual-channel listings may help identify where a medicine is dispensed, but they do not automatically establish reimbursement eligibility or a specific price for an international self-paying patient.
What travel documents are required for international patients receiving care in China?
Patients must secure the appropriate visa or entry documentation, depending on their nationality, intended length of stay, travel circumstances, and any supporting documents provided by the receiving hospital. For more detailed planning, patients can review our S1/S2 visa application guide and our China visa-free medical travel guide. Eligibility, documentation requirements, and final entry decisions are determined by the relevant consular and border authorities.
Urgent Care Notice: MedBridgeNZ does not provide emergency medical services. Patients with rapidly worsening symptoms, severe side effects, or an immediate medical concern should seek urgent care from their local medical team rather than waiting for cross-border coordination.
Request an Administrative Case Intake
Submit your diagnosis summary, latest medical records, treatment history, country of residence, and the medicine or treatment pathway you wish to explore. Our bilingual Patient Care Team will explain the record-preparation and hospital-contact process. Hospital acceptance, clinical suitability, and medicine availability cannot be guaranteed.
References
National Medical Products Administration. Drug Administration Law of the People’s Republic of China.https://english.nmpa.gov.cn/2019-09/26/c_773012_2.htm
National Healthcare Security Administration. NHSA and the Ministry of Human Resources and Social Security Issue the 2024 National Reimbursement Drug List.https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html
National Healthcare Security Administration. State Council Information Office Policy Briefing on Improving the Whole-Cycle, Whole-Channel Drug Pricing Mechanism.https://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html
National Health Commission of the People’s Republic of China. Provisions on the Administration of Pharmaceutical Affairs in Medical Institutions.https://www.nhc.gov.cn/wjw/gfxwj/201103/3df77cb6091b4694be3afd8fcd68a4b5/files/1733384571188_76038.doc
National Healthcare Security Administration and National Health Commission. Guiding Opinions on Establishing and Improving the “Dual-Channel” Management Mechanism for Nationally Negotiated Medicines.https://www.nhsa.gov.cn/art/2021/5/10/art_53_5028.html
Hainan Medical Products Administration and Hainan Provincial Health Commission. Measures for the Administration of Take-Home Use of Clinically Urgently Needed Imported Drugs and Medical Devices in the Boao Lecheng International Medical Tourism Pilot Zone.https://amr.hainan.gov.cn/himpa/xxgk/zfwj/bmwj/202311/t20231129_3537640.html
U.S. Food and Drug Administration. Personal Importation.https://www.fda.gov/importeddrugs
Health Canada. Bringing Health Products into Canada for Personal Use (GUI-0116).https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/importation-exportation/personal-use-health-products-guidance/document.html
Australian Therapeutic Goods Administration. Personal Importation Scheme.https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme
New Zealand Medicines and Medical Devices Safety Authority. Importing Medicines.https://www.medsafe.govt.nz/Consumers/miet/importmedicines.asp
Important Notice: MedBridgeNZ is an international medical concierge and logistics coordination service. We do not diagnose medical conditions, recommend treatments, determine medicine suitability, prescribe or dispense medicines, or act as a pharmacy, medicine seller, importer, or exporter. We do not purchase, store, resell, or ship prescription medicines. Clinical suitability, prescribing, dispensing, treatment, and travel fitness are determined by licensed clinicians, hospitals, and pharmacies. Medicine availability, prices, appointment timelines, and cross-border rules may change and cannot be guaranteed. This page provides general information only and is not medical, legal, customs, or pricing advice. Always consult your primary physician or treating medical team before pursuing cross-border treatment options.
